Also on a side note how much of a risk is Shulgin taking testing each new drug on himself?
I don't think the risk Dr. Shulgin took was as high as most assume. Many read P/TiHKAL and assume he was blindly consuming these compounds. 1) He began dosing from microgram doses and worked his way up over time 2) studies had been done on some, if not most, of the compounds by himself and others since the early 1960s or some are from old references, patents, studies, and so forth of abandoned compounds, and 3) he did not consume every single compound himself - some are excerpts from previous trials, not limited to
MK-ULTRA (eg. 5-HO-DMT). Though he has self-administered a lot of them with his group.
how hard/easy would it be to create a recreational drug with specific properties (say similar to ecstasy) from scratch?
If 'from scratch' means a new untested molecular family, it would be very difficult. Even if one knew the structure-activity relation (SAR) and had the receptor docking model for a compound it does not; 1) limit it's activity to this site only, meaning it could activate other site(s) causing potential contradicting (side) effect(s) to the target (see
pharmacodynamic) or 2) guarantee it will ever reach the site, ie. crossing blood brain barrier, metabolization, distribution/absorption, etc (see
pharmacokinetics. If you mean a new molecule but based off of an existing drug(s), this is much more plausible, however still not a simple task. There is simply too much that needs to be considered with a living system.
If you are interested in this field, please pursue it with the formal chemistry, biology, and pharmacology education.
I don't remember enough details to easily locate the story, but somewhere in the sixties or seventies group of students tried to synthesize a modified version of a known drug. Long story short - several people died, several were paralyzed.
Pethidine analogue,
MPPP's byproduct metabolite. Another case, at the pharmaceutical level, is
fenfluramine which is based off of amphetamine analogues. I believe 5-HT
2B activity has since become standard in the pre-clinical stage testing for new drugs - or am I incorrect?